Asia Pacific Multiple Sclerosis Drugs Market

Home Healthcare And Pharmaceutical Asia Pacific Multiple Sclerosis Drugs Market

Asia Pacific Multiple Sclerosis Drugs Market, By Disease Type (Relapsing-Remitting Multiple Sclerosis (RRMS), Secondary Progressive Multiple Sclerosis (SPMS), Primary Progressive Multiple Sclerosis (PPMS), Severe Relapsing-Remitting Multiple Sclerosis (RES)); By Treatment (Preventive Therapies, Abortive Therapies/Treatment of Acute Exacerbations, Symptomatic Therapies); By Drug Type (Branded, Generic); By End User (Hospital & Clinics, Diagnostic Laboratories); By Country (China, India, Japan, South Korea, Australia & New Zealand, Indonesia, Malaysia, Singapore, Vietnam, Rest of APAC), Competitive Landscape & Forecast, 2019–2029

Published Date: November 2023
Report ID: BWC23912
Available Format: PDF
Page: 200

Report Overview

Increasing incidence of multiple sclerosis, growing awareness and diagnosis rates, expanding healthcare infrastructure, and advancements in drug therapies. Rising healthcare expenditure and a large patient population contribute to the growth of Asia-Pacific Multiple Sclerosis Drugs Market during the forecast period between 2023 and 2029.

Asia-Pacific Multiple Sclerosis Drugs Market – Industry Trends & Forecast Report, 2029

Asia-Pacific multiple sclerosis drugs market size was estimated at USD 4.09 billion in 2022. During the forecast period between 2023 and 2029, the size of Asia-Pacific multiple sclerosis drugs market is projected to grow at a CAGR of 8.65% reaching a value of USD 6.72 billion by 2029. Asia-Pacific multiple sclerosis drugs market is influenced by several key factors. A rising incidence of multiple sclerosis in the region drives market growth. Also, increased awareness and early diagnosis contribute to higher demand for MS drugs. Advancements in healthcare infrastructure expanded access to healthcare services, and government initiatives supporting neurology research and treatment further boosted the market. Collaboration between pharmaceutical companies and research institutions fosters innovation in drug development. Further, the growing aging population and changing lifestyles increase the patient pool, creating a sustained demand for multiple sclerosis drugs in the Asia-Pacific region.

Asia Pacific Multiple Sclerosis Drugs Market

Multiple Sclerosis Drugs - Overview

Multiple sclerosis (MS) drugs aim to manage the chronic autoimmune disease that affects the central nervous system. They fall into several categories, including disease-modifying therapies (DMTs), which slow the progression of MS and reduce relapses. Common DMTs include interferons, oral medications like fingolimod, and monoclonal antibodies such as ocrelizumab. Symptomatic treatments alleviate specific MS symptoms, like muscle spasms and fatigue. These drugs can improve a patient's quality of life but don't alter the course of the disease. A comprehensive approach to MS management typically combines DMTs and symptomatic treatments, tailored to each patient's specific needs and disease progression.

Asia-Pacific Multiple Sclerosis Market

Growth Drivers

Innovative Telemedicine Initiatives

Asia-Pacific multiple sclerosis drugs market is experiencing a unique growth driver through the rapid adoption of innovative telemedicine initiatives. As healthcare systems and technology infrastructure continue to advance in the region, telemedicine is enhancing accessibility to specialist care for multiple sclerosis patients, bridging geographical gaps, and improving treatment outcomes. This approach not only facilitates early diagnosis and treatment but also enables continuous monitoring and personalized care, driving demand for MS drugs. Further, it reduces the burden on in-person healthcare visits, making treatment more convenient for patients and boosting the market's expansion across the Asia-Pacific region.

Restraints

Limited Accessibility to Advanced Treatment Options

Asia-Pacific multiple sclerosis drugs market faces a unique restraint in the form of limited accessibility to advanced treatment options. While the region's growing prevalence of multiple sclerosis demands effective pharmaceutical solutions, disparities in healthcare infrastructure and distribution networks hinder patients' access to cutting-edge medications. Varied regulations, economic disparities, and cultural factors contribute to the challenge of ensuring equitable drug availability across the diverse Asia-Pacific landscape. Overcoming these accessibility barriers remains a pivotal concern for both pharmaceutical companies and healthcare providers seeking to address the increasing burden of multiple sclerosis in the region.

Impact of COVID-19 on Asia-Pacific Multiple Sclerosis Drugs Market

Asia-Pacific multiple sclerosis drugs market significantly shifts due to the COVID-19 pandemic. The market faced disruptions in supply chains, delayed clinical trials, and altered patient care dynamics, impacting drug availability and treatment continuity. Telemedicine and home-based treatments gained prominence, while healthcare systems adapted to new safety measures. Despite these challenges, the market showed resilience, with increased research and development efforts to address the unique needs of multiple sclerosis patients in the Asia-Pacific region. The pandemic underscored the importance of adaptable healthcare strategies and accelerated digital transformations in the industry.

Asia-Pacific Multiple Sclerosis Drugs Market

Segmental Coverage

Asia-Pacific Multiple Sclerosis Drugs Market – By Disease Type

Based on disease type, Asia-Pacific multiple sclerosis drugs market is divided into Relapsing-Remitting Multiple Sclerosis (RRMS), Secondary Progressive Multiple Sclerosis (SPMS), Primary Progressive Multiple Sclerosis (PPMS), Severe Relapsing-Remitting Multiple Sclerosis (RES) segments. Relapsing-Remitting Multiple Sclerosis (RRMS) is the largest disease type, which encompasses a significant portion of the market. RRMS is a common form of multiple sclerosis, characterized by periods of symptom relapse and remission. This segment represents a substantial patient population in the region, driving the demand for drugs and treatments aimed at managing and alleviating the condition's symptoms. While other segments like Secondary Progressive Multiple Sclerosis (SPMS), Primary Progressive Multiple Sclerosis (PPMS), and Severe Relapsing-Remitting Multiple Sclerosis (RES) also play vital roles, RRMS remains the dominant focus in the Asia-Pacific multiple sclerosis drug market.

Asia-Pacific Multiple Sclerosis Drugs Market – By Treatment

By treatment, Asia-Pacific multiple sclerosis drugs market is divided into Preventive Therapies, Abortive Therapies/Treatment of Acute Exacerbations, and Symptomatic Therapies segments. Preventive Therapies constitute the largest segment and they aim at reducing the frequency and severity of multiple sclerosis (MS) relapses, making them a pivotal component of managing the disease. They include disease-modifying drugs that work to slow down the progression of MS and reduce inflammation. This segment's prominence reflects the growing importance of long-term management and the need to prevent MS exacerbations, ultimately improving the quality of life for patients in the Asia-Pacific region.

Asia Pacific Multiple Sclerosis Drugs Market Size

Asia-Pacific Multiple Sclerosis Drugs Market – By Drug Type

By drug type, Asia-Pacific multiple sclerosis drugs market is divided into Branded and Generic segments. The branded segment comprises patented medications developed by pharmaceutical companies, often with higher prices due to research and development costs. In contrast, the Generic segment includes lower-cost alternatives once patents expire, offering more affordable treatment options. The market's largest segment can vary over time due to factors like patent expirations and the introduction of new medications, but both segments play crucial roles in addressing the healthcare needs of multiple sclerosis patients in the region.

Asia-Pacific Multiple Sclerosis Drugs Market – By End User

By end user, Asia-Pacific multiple sclerosis drugs market is divided into Hospital and Clinics, and Diagnostic Laboratories segments. These segments play pivotal roles in the diagnosis and treatment of multiple sclerosis within the region. Hospitals and Clinics offer essential medical care and therapeutic services to patients with multiple sclerosis, while Diagnostic Laboratories provide critical testing and diagnostic support. The market's largest segment can vary depending on factors such as regional healthcare infrastructure and patient preferences, with both segments contributing significantly to the overall management of multiple sclerosis in the Asia-Pacific region.

Asia-Pacific Multiple Sclerosis Drugs Market – By Country

Geographically, Asia-Pacific multiple sclerosis drugs market is divided into China, India, Japan, South Korea, Australia & New Zealand, Indonesia, Malaysia, Singapore, Vietnam, and Rest of APAC. China is the largest country in the Asia-Pacific multiple sclerosis drugs market. This vast and populous country represents a significant portion of the market due to its large population and growing healthcare infrastructure. China's increasing awareness of multiple sclerosis, coupled with a rising patient pool, has fueled demand for MS drugs. The nation's robust pharmaceutical industry and healthcare investments make it a key player in the market. While other countries in the region, such as India and Japan, also contribute significantly, China stands out as the dominant market segment in the rapidly evolving landscape of multiple sclerosis treatment in the Asia-Pacific region.

Competitive Landscape

Major players in the Asia-Pacific multiple sclerosis drugs market include Biogen, Sanofi, Novartis, Mitsubishi Tanabe Pharma, Merck Group, Sun Pharmaceutical Industries Ltd, Teva Pharmaceutical Industries, Sawai Pharmaceutical Co., Ltd, Meiji Seika Pharma Co., Ltd, and LG Chem Life Sciences. To grow their market share, these companies are also focusing on investing in innovations, collaborations, and expansions.

Scope of the Report

Attributes	Details
Years Considered	Historical Data – 2019–2022
	Base Year – 2022
	Estimated Year – 2023
	Forecast Period – 2023–2029
Facts Covered	Revenue in USD Million
Market Coverage	China, India, Japan, South Korea, Australia & New Zealand, Indonesia, Malaysia, Singapore, Vietnam, Rest of APAC
Product/ Service Segmentation	Disease Type, Treatment, Drug Type, End-User, Country
Key Players	Biogen, Sanofi, Novartis, Mitsubishi Tanabe Pharma, Merck Group, Sun Pharmaceutical Industries Ltd, Teva Pharmaceutical Industries, Sawai Pharmaceutical Co., Ltd, Meiji Seika Pharma Co., Ltd, LG Chem Life Sciences

By Disease Type

Relapsing-Remitting Multiple Sclerosis (RRMS)
Secondary Progressive Multiple Sclerosis (SPMS)
Primary Progressive Multiple Sclerosis (PPMS)
Severe Relapsing-Remitting Multiple Sclerosis (RES)

By Treatment

Preventive Therapies
Abortive Therapies/Treatment of Acute Exacerbations
Symptomatic Therapies

By Drug Type

Branded
Generic

By End User

Hospital and Clinics
Diagnostic Laboratories

By Country

China
India
Japan
South Korea
Australia & New Zealand
Indonesia
Malaysia
Singapore
Vietnam
Rest of APAC

Research Framework
1. Research Objective
2. Product Overview
3. Market Segmentation
Executive Summary
Asia-Pacific Multiple Sclerosis Drugs Market Insights
1. Industry Value Chain Analysis
2. DROC Analysis
  1. Growth Drivers
    1. Increasing awareness about multiple sclerosis
    2. Increasing number of prospective pipeline drug development projects
  2. Restraints
    1. High treatment expenditure
    2. Limited access to high-cost therapies
  3. Opportunity
    1. Increasing demand of branded drugs
    2. Rapid advancements in the healthcare industry
  4. Challenges
    1. Lack of diagnosis and awareness
3. Technological Advancements/Recent Developments
4. Regulatory Framework
5. Porter’s Five Forces Analysis
  1. Bargaining Power of Suppliers
  2. Bargaining Power of Buyers
  3. Threat of New Entrants
  4. Threat of Substitutes
  5. Intensity of Rivalry
Asia-Pacific Multiple Sclerosis Drugs Market Overview
1. Market Size & Forecast by Value & Volume, 2019–2029
  1. By Value (USD Million)
2. Market Share & Forecast
  1. By Disease Type
    1. Relapsing–Remitting Multiple Sclerosis (RRMS)
    2. Secondary Progressive Multiple Sclerosis (SPMS)
    3. Primary Progressive Multiple Sclerosis (PPMS)
    4. Severe Relapsing–Remitting Multiple Sclerosis (RES)
  2. By Treatment
    1. Preventive Therapies
    2. Abortive Therapies/Treatment of Acute Exacerbations
    3. Symptomatic Therapies
  3. By Drug Type
    1. Branded
    2. Generic
  4. By End User
    1. Hospital and Clinics
    2. Diagnostic Laboratories
    3. Others
  5. By Country
    1. China
    2. India
    3. Japan
    4. South Korea
    5. Australia & New Zealand
    6. Indonesia
    7. Malaysia
    8. Singapore
    9. Vietnam
    10. Rest of APAC
China Multiple Sclerosis Drugs Market Overview
1. Market Size & Forecast by Value & Volume, 2019–2029
  1. By Value (USD Million)
2. Market Share & Forecast
  1. By Disease Type
  2. By Treatment
  3. By Drug Type
  4. By End User
India Multiple Sclerosis Drugs Market Overview
1. Market Size & Forecast by Value & Volume, 2019–2029
  1. By Value (USD Million)
2. Market Share & Forecast
  1. By Disease Type
  2. By Treatment
  3. By Drug Type
  4. By End User
Japan Multiple Sclerosis Drugs Market Overview
1. Market Size & Forecast by Value & Volume, 2019–2029
  1. By Value (USD Million)
2. Market Share & Forecast
  1. By Disease Type
  2. By Treatment
  3. By Drug Type
  4. By End User
South Korea Multiple Sclerosis Drugs Market Overview
1. Market Size & Forecast by Value & Volume, 2019–2029
  1. By Value (USD Million)
2. Market Share & Forecast
  1. By Disease Type
  2. By Treatment
  3. By Drug Type
  4. By End User
Australia & New Zealand Multiple Sclerosis Drugs Market Overview
1. Market Size & Forecast by Value & Volume, 2019–2029
  1. By Value (USD Million)
2. Market Share & Forecast
  1. By Disease Type
  2. By Treatment
  3. By Drug Type
  4. By End User
Indonesia Multiple Sclerosis Drugs Market Overview
1. Market Size & Forecast by Value & Volume, 2019–2029
  1. By Value (USD Million)
2. Market Share & Forecast
  1. By Disease Type
  2. By Treatment
  3. By Drug Type
  4. By End User
Malaysia Multiple Sclerosis Drugs Market Overview
1. Market Size & Forecast by Value & Volume, 2019–2029
  1. By Value (USD Million)
2. Market Share & Forecast
  1. By Disease Type
  2. By Treatment
  3. By Drug Type
  4. By End User
Singapore Multiple Sclerosis Drugs Market Overview
1. Market Size & Forecast by Value & Volume, 2019–2029
  1. By Value (USD Million)
2. Market Share & Forecast
  1. By Disease Type
  2. By Treatment
  3. By Drug Type
  4. By End User
Vietnam Multiple Sclerosis Drugs Market Overview
1. Market Size & Forecast by Value & Volume, 2019–2029
  1. By Value (USD Million)
2. Market Share & Forecast
  1. By Disease Type
  2. By Treatment
  3. By Drug Type
  4. By End User
Rest of APAC Multiple Sclerosis Drugs Market Overview
1. Market Size & Forecast by Value & Volume, 2019–2029
  1. By Value (USD Million)
2. Market Share & Forecast
  1. By Disease Type
  2. By Treatment
  3. By Drug Type
  4. By End User
Competitive Landscape
1. List of Key Players and Their Offerings
2. Asia-Pacific Multiple Sclerosis Drugs Company Market Share Analysis, 2022
3. Competitive Benchmarking, By Operating Parameters
4. Key Strategic Development (Mergers, Acquisitions, Partnerships, etc.)
Impact of Covid-19 on Asia-Pacific Multiple Sclerosis Drugs Market
Company Profile (Company Overview, Financial Matrix, Competitive landscape, Key Personnel, Key Competitors, Contact Address, Strategic Outlook and SWOT Analysis)
1. Biogen
2. Sanof
3. Novartis
4. Mitsubishi Tanabe Pharma
5. Merck Group
6. Sun Pharmaceutical Industries Ltd
7. Teva Pharmaceutical Industries
8. Sawai Pharmaceutical Co., Ltd
9. Meiji Seika Pharma Co., Ltd
10. LG Chem Life Sciences
11. Other Prominent Players
Key Strategic Recommendations
Research Methodology
1. Qualitative Research
  1. Primary & Secondary Research
2. Quantitative Research
3. Market Breakdown & Data Triangulation
  1. Secondary Research
  2. Primary Research
4. Breakdown of Primary Research Respondents, By Region
5. Assumption & Limitation

*Financial information of non-listed companies will be provided as per availability

**The segmentation and the companies are subjected to modifications based on in-depth secondary for the final deliverable

List of Figures

Figure 1 Asia-Pacific Multiple Sclerosis Drugs Market Segmentation

Figure 2 Asia-Pacific Multiple Sclerosis Drugs Market Value Chain Analysis

Figure 3 Company Market Share Analysis, 2022

Figure 4 Asia-Pacific Multiple Sclerosis Drugs Market Size, By Value (USD Billion), 2019–2029

Figure 5 Asia-Pacific Multiple Sclerosis Drugs Market Share, By Disease Type, By Value, 2019–2029

Figure 6 Asia-Pacific Multiple Sclerosis Drugs Market Share, By Treatment, By Value, 2019–2029

Figure 7 Asia-Pacific Multiple Sclerosis Drugs Market Share, By Drug Type, By Value, 2019–2029

Figure 8 Asia-Pacific Multiple Sclerosis Drugs Market Share, By End User, By Value, 2019–2029

Figure 9 Asia-Pacific Multiple Sclerosis Drugs Market Share, By Country, By Value, 2019–2029

Figure 10 China Multiple Sclerosis Drugs Market Size, By Value (USD Billion), 2019–2029

Figure 11 China Multiple Sclerosis Drugs Market Share, By Disease Type, By Value, 2019–2029

Figure 12 China Multiple Sclerosis Drugs Market Share, By Treatment, By Value, 2019–2029

Figure 13 China Multiple Sclerosis Drugs Market Share, By Drug Type, By Value, 2019–2029

Figure 14 China Multiple Sclerosis Drugs Market Share, By End User, By Value, 2019–2029

Figure 15 India Multiple Sclerosis Drugs Market Size, By Value (USD Billion), 2019–2029

Figure 16 India Multiple Sclerosis Drugs Market Share, By Disease Type, By Value, 2019–2029

Figure 17 India Multiple Sclerosis Drugs Market Share, By Treatment, By Value, 2019–2029

Figure 18 India Multiple Sclerosis Drugs Market Share, By Drug Type, By Value, 2019–2029

Figure 19 India Multiple Sclerosis Drugs Market Share, By End User, By Value, 2019–2029

Figure 20 Japan Multiple Sclerosis Drugs Market Size, By Value (USD Billion), 2019–2029

Figure 21 Japan Multiple Sclerosis Drugs Market Share, By Disease Type, By Value, 2019–2029

Figure 22 Japan Multiple Sclerosis Drugs Market Share, By Treatment, By Value, 2019–2029

Figure 23 Japan Multiple Sclerosis Drugs Market Share, By Drug Type, By Value, 2019–2029

Figure 24 Japan Multiple Sclerosis Drugs Market Share, By End User, By Value, 2019–2029

Figure 25 South Korea Multiple Sclerosis Drugs Market Size, By Value (USD Billion), 2019–2029

Figure 26 South Korea Multiple Sclerosis Drugs Market Share, By Disease Type, By Value, 2019–2029

Figure 27 South Korea Multiple Sclerosis Drugs Market Share, By Treatment, By Value, 2019–2029

Figure 28 South Korea Multiple Sclerosis Drugs Market Share, By Drug Type, By Value, 2019–2029

Figure 29 South Korea Multiple Sclerosis Drugs Market Share, By End User, By Value, 2019–2029

Figure 30 Australia & New Zealand Multiple Sclerosis Drugs Market Size, By Value (USD Billion), 2019–2029

Figure 31 Australia & New Zealand Multiple Sclerosis Drugs Market Share, By Disease Type, By Value, 2019–2029

Figure 32 Australia & New Zealand Multiple Sclerosis Drugs Market Share, By Treatment, By Value, 2019–2029

Figure 33 Australia & New Zealand Multiple Sclerosis Drugs Market Share, By Drug Type, By Value, 2019–2029

Figure 34 Australia & New Zealand Multiple Sclerosis Drugs Market Share, By End User, By Value, 2019–2029

Figure 35 Indonesia Multiple Sclerosis Drugs Market Size, By Value (USD Billion), 2019–2029

Figure 36 Indonesia Multiple Sclerosis Drugs Market Share, By Disease Type, By Value, 2019–2029

Figure 37 Indonesia Multiple Sclerosis Drugs Market Share, By Treatment, By Value, 2019–2029

Figure 38 Indonesia Multiple Sclerosis Drugs Market Share, By Drug Type, By Value, 2019–2029

Figure 39 Indonesia Multiple Sclerosis Drugs Market Share, By End User, By Value, 2019–2029

Figure 40 Malaysia Multiple Sclerosis Drugs Market Size, By Value (USD Billion), 2019–2029

Figure 41 Malaysia Multiple Sclerosis Drugs Market Share, By Disease Type, By Value, 2019–2029

Figure 42 Malaysia Multiple Sclerosis Drugs Market Share, By Treatment, By Value, 2019–2029

Figure 43 Malaysia Multiple Sclerosis Drugs Market Share, By Drug Type, By Value, 2019–2029

Figure 44 Malaysia Multiple Sclerosis Drugs Market Share, By End User, By Value, 2019–2029

Figure 45 Singapore Multiple Sclerosis Drugs Market Size, By Value (USD Billion), 2019–2029

Figure 46 Singapore Multiple Sclerosis Drugs Market Share, By Disease Type, By Value, 2019–2029

Figure 47 Singapore Multiple Sclerosis Drugs Market Share, By Treatment, By Value, 2019–2029

Figure 48 Singapore Multiple Sclerosis Drugs Market Share, By Drug Type, By Value, 2019–2029

Figure 49 Singapore Multiple Sclerosis Drugs Market Share, By End User, By Value, 2019–2029

Figure 50 Vietnam Multiple Sclerosis Drugs Market Size, By Value (USD Billion), 2019–2029

Figure 51 Vietnam Multiple Sclerosis Drugs Market Share, By Disease Type, By Value, 2019–2029

Figure 52 Vietnam Multiple Sclerosis Drugs Market Share, By Treatment, By Value, 2019–2029

Figure 53 Vietnam Multiple Sclerosis Drugs Market Share, By Drug Type, By Value, 2019–2029

Figure 54 Vietnam Multiple Sclerosis Drugs Market Share, By End User, By Value, 2019–2029

Figure 55 Rest of Asia-Pacific Multiple Sclerosis Drugs Market Size, By Value (USD Billion), 2019–2029

Figure 56 Rest of Asia-Pacific Multiple Sclerosis Drugs Market Share, By Disease Type, By Value, 2019–2029

Figure 57 Rest of Asia-Pacific Multiple Sclerosis Drugs Market Share, By Treatment, By Value, 2019–2029

Figure 58 Rest of Asia-Pacific Multiple Sclerosis Drugs Market Share, By Drug Type, By Value, 2019–2029

Figure 59 Rest of Asia-Pacific Multiple Sclerosis Drugs Market Share, By End User, By Value, 2019–2029

List of Tables

Table 1 Asia-Pacific Multiple Sclerosis Drugs Market Size, By Disease Type, By Value, 2019–2029

Table 2 Asia-Pacific Multiple Sclerosis Drugs Market Size, By Treatment, By Value, 2019–2029

Table 3 Asia-Pacific Multiple Sclerosis Drugs Market Size, By Drug Type, By Value, 2019–2029

Table 4 Asia-Pacific Multiple Sclerosis Drugs Market Size, By End User, By Value, 2019–2029

Table 5 Asia-Pacific Multiple Sclerosis Drugs Market Size, By Country, By Value, 2019–2029

Table 6 China Multiple Sclerosis Drugs Market Size, By Disease Type, By Value, 2019–2029

Table 7 China Multiple Sclerosis Drugs Market Size, By Treatment, By Value, 2019–2029

Table 8 China Multiple Sclerosis Drugs Market Size, By Drug Type, By Value, 2019–2029

Table 9 China Multiple Sclerosis Drugs Market Size, By End User, By Value, 2019–2029

Table 10 India Multiple Sclerosis Drugs Market Size, By Disease Type, By Value, 2019–2029

Table 11 India Multiple Sclerosis Drugs Market Size, By Treatment, By Value, 2019–2029

Table 12 India Multiple Sclerosis Drugs Market Size, By Drug Type, By Value, 2019–2029

Table 13 India Multiple Sclerosis Drugs Market Size, By End User, By Value, 2019–2029

Table 14 Japan Multiple Sclerosis Drugs Market Size, By Disease Type, By Value, 2019–2029

Table 15 Japan Multiple Sclerosis Drugs Market Size, By Treatment, By Value, 2019–2029

Table 16 Japan Multiple Sclerosis Drugs Market Size, By Drug Type, By Value, 2019–2029

Table 17 Japan Multiple Sclerosis Drugs Market Size, By End User, By Value, 2019–2029

Table 18 South Korea Multiple Sclerosis Drugs Market Size, By Disease Type, By Value, 2019–2029

Table 19 South Korea Multiple Sclerosis Drugs Market Size, By Treatment, By Value, 2019–2029

Table 20 South Korea Multiple Sclerosis Drugs Market Size, By Drug Type, By Value, 2019–2029

Table 21 South Korea Multiple Sclerosis Drugs Market Size, By End User, By Value, 2019–2029

Table 22 Australia & New Zealand Multiple Sclerosis Drugs Market Size, By Disease Type, By Value, 2019–2029

Table 23 Australia & New Zealand Multiple Sclerosis Drugs Market Size, By Treatment, By Value, 2019–2029

Table 24 Australia & New Zealand Multiple Sclerosis Drugs Market Size, By Drug Type, By Value, 2019–2029

Table 25 Australia & New Zealand Multiple Sclerosis Drugs Market Size, By End User, By Value, 2019–2029

Table 26 Indonesia Multiple Sclerosis Drugs Market Size, By Disease Type, By Value, 2019–2029

Table 27 Indonesia Multiple Sclerosis Drugs Market Size, By Treatment, By Value, 2019–2029

Table 28 Indonesia Multiple Sclerosis Drugs Market Size, By Drug Type, By Value, 2019–2029

Table 29 Indonesia Multiple Sclerosis Drugs Market Size, By End User, By Value, 2019–2029

Table 30 Malaysia Multiple Sclerosis Drugs Market Size, By Disease Type, By Value, 2019–2029

Table 31 Malaysia Multiple Sclerosis Drugs Market Size, By Treatment, By Value, 2019–2029

Table 32 Malaysia Multiple Sclerosis Drugs Market Size, By Drug Type, By Value, 2019–2029

Table 33 Malaysia Multiple Sclerosis Drugs Market Size, By End User, By Value, 2019–2029

Table 34 Singapore Multiple Sclerosis Drugs Market Size, By Disease Type, By Value, 2019–2029

Table 35 Singapore Multiple Sclerosis Drugs Market Size, By Treatment, By Value, 2019–2029

Table 36 Singapore Multiple Sclerosis Drugs Market Size, By Drug Type, By Value, 2019–2029

Table 37 Singapore Multiple Sclerosis Drugs Market Size, By End User, By Value, 2019–2029

Table 38 Vietnam Multiple Sclerosis Drugs Market Size, By Disease Type, By Value, 2019–2029

Table 39 Vietnam Multiple Sclerosis Drugs Market Size, By Treatment, By Value, 2019–2029

Table 40 Vietnam Multiple Sclerosis Drugs Market Size, By Drug Type, By Value, 2019–2029

Table 41 Vietnam Multiple Sclerosis Drugs Market Size, By End User, By Value, 2019–2029

Table 42 Rest of Asia-Pacific Multiple Sclerosis Drugs Market Size, By Disease Type, By Value, 2019–2029

Table 43 Rest of Asia-Pacific Multiple Sclerosis Drugs Market Size, By Treatment, By Value, 2019–2029

Table 44 Rest of Asia-Pacific Multiple Sclerosis Drugs Market Size, By Drug Type, By Value, 2019–2029

Table 45 Rest of Asia-Pacific Multiple Sclerosis Drugs Market Size, By End User, By Value, 2019–2029

Table 47 Biogen Company Overview

Table 48 Biogen Financial Overview

Table 49 Sanof Company Overview

Table 50 Sanof Financial Overview

Table 51 Novartis Company Overview

Table 52 Novartis Financial Overview

Table 53 Mitsubishi Tanabe Pharma Company Overview

Table 54 Mitsubishi Tanabe Pharma Financial Overview

Table 55 Merck Group Company Overview

Table 56 Merck Group Financial Overview

Table 57 Sun Pharmaceutical Industries Ltd Company Overview

Table 58 Sun Pharmaceutical Industries Ltd Financial Overview

Table 59 Teva Pharmaceutical Industries Company Overview

Table 60 Teva Pharmaceutical Industries Financial Overview

Table 61 Sawai Pharmaceutical Co., Ltd Company Overview

Table 62 Sawai Pharmaceutical Co., Ltd Financial Overview

Table 63 Meiji Seika Pharma Co., Ltd Company Overview

Table 64 Meiji Seika Pharma Co., Ltd Financial Overview

Table 65 LG Chem Life Sciences Company Overview

Table 66 LG Chem Life Sciences Financial Overview

Market Segmentation

No data available

To request a free sample copy of this report, please complete the form below.

We value your investment and offer free customization with every report to fulfil your exact research needs.

Yes, I have read the privacy policy

This website is secure and your personal details are safe.

Frequently Asked Questions (FAQs):

1. What is the current market size of Asia-Pacific Multiple Sclerosis Drugs Market?

Ans: Asia-Pacific Multiple Sclerosis Drugs Market size was estimated at USD 4.09 billion in 2022.

2. What is the expected CAGR of Asia-Pacific Multiple Sclerosis Drugs Market during the forecast period?

Ans: Asia-Pacific Multiple Sclerosis Drugs Market size is expected to grow at a CAGR of 8.65% during the forecast period between 2023 and 2029.

3. What is the forecast value of Asia-Pacific Multiple Sclerosis Drugs Market size by 2029?

Ans: Asia-Pacific Multiple Sclerosis Drugs Market size is expected to reach a value of USD 6.72 billion by 2029.

4. What are the major factors driving the growth of Asia-Pacific Multiple Sclerosis Drugs Market?

Ans: Major factors driving the growth of the Asia-Pacific Multiple Sclerosis Drugs Market include increasing incidence of multiple sclerosis, growing awareness and diagnosis rates, expanding healthcare infrastructure, and advancements in drug therapies. Rising healthcare expenditure and a large patient population contribute to market growth.

5. Name the key players in Asia-Pacific Multiple Sclerosis Drugs Market.

Ans: Key players in the Asia-Pacific Multiple Sclerosis Drugs Market include Biogen, Sanofi, Novartis, Mitsubishi Tanabe Pharma, Merck Group, Sun Pharmaceutical Industries Ltd, Teva Pharmaceutical Industries, Sawai Pharmaceutical Co., Ltd, Meiji Seika Pharma Co., Ltd, and LG Chem Life Sciences.

6. Which is the leading drug type segment in Asia-Pacific Multiple Sclerosis Drugs Market?

Ans: The branded hold a higher market share in the Asia-Pacific Multiple Sclerosis Drugs Market by drug type.

7. Which is the leading country in Asia-Pacific Multiple Sclerosis Drugs Market?

Ans: China holds the highest market share in the Asia-Pacific Multiple Sclerosis Drugs Market.

PLACE AN ORDER

SINGLE USER LICENSE
$ 3599
GROUP LICENSE
$ 4000
ENTERPRISE LICENSE
$ 4500
EXCEL DATA PACK
$ 2100

Request for Sample

RELATED REPORTS

WHY CHOOSE US

24/7 Research Support

Get your queries resolved from an industry expert. Request for a free product review before report purchase.
Custom Research Service

Ask the Analyst to customize an exclusive study to serve your research needs
Quality & Accuracy

Ask the Analyst to customize an exclusive study to serve your research needs
Data Visualization

As the business world is changing dynamically every day. We need to stay pin point in relation to data management and optimum data utilization
Information security

We never share your personal and confidential information. Your personal information is safe and secure with us.

Asia Pacific Multiple Sclerosis Drugs Market

Report Overview

Market Segmentation

To request a free sample copy of this report, please complete the form below.

Frequently Asked Questions (FAQs):

1. What is the current market size of Asia-Pacific Multiple Sclerosis Drugs Market?

2. What is the expected CAGR of Asia-Pacific Multiple Sclerosis Drugs Market during the forecast period?

3. What is the forecast value of Asia-Pacific Multiple Sclerosis Drugs Market size by 2029?

4. What are the major factors driving the growth of Asia-Pacific Multiple Sclerosis Drugs Market?

5. Name the key players in Asia-Pacific Multiple Sclerosis Drugs Market.

6. Which is the leading drug type segment in Asia-Pacific Multiple Sclerosis Drugs Market?

7. Which is the leading country in Asia-Pacific Multiple Sclerosis Drugs Market?

PLACE AN ORDER

RELATED REPORTS

WHY CHOOSE US

24/7 Research Support

Custom Research Service

Quality & Accuracy

Data Visualization

Information security